

17 June 2026

Treatments for Migraine

A. How many patients have been treated with the following drugs in the past 4 months:

Figures provided are for February to May 2026

- **Atogepant (Aquipta) – any disease**
 - 43 patients
- **Erenumab (Aimovig) - any disease**
 - No patients commenced within the past 4 months. Treatment now available
– 1st patient commenced 3/6/2026
- **Eptinezumab (Vyepiti) – any disease**
 - No patients have been commenced to date
- **Fremanezumab (Ajovy) - any disease**
 - No patients have been commenced to date
- **Galcanezumab (Emgality) - any disease**
 - 26 patients
- **Rimegepant (Vydura) – any disease**
 - 20 patients
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**
 - 148 patients (21 patients 1st Cycle)

B. How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month)

	Chronic Migraine (15+ headache days/month)
Atogepant	43
Erenumab	0
Eptinezumab	0
Fremanezumab	0
Galcanezumab	26
Rimegepant	0 (Only used to treat Episodic)



17 June 2026

	and acute Migraine)
Botulinum Toxin	148

C. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**
 - 20 patients